TY - JOUR AU - Müller, David AU - Shin, Sauyeun AU - Goullet de Rugy, Théo AU - Samain, Rémi AU - Baer, Romain AU - Strehaiano, Manon AU - Masvidal-Sanz, Laia AU - Guillermet-Guibert, Julie AU - Jean, Christine AU - Tsukumo, Yoshinori AU - Sonenberg, Nahum AU - Marion, Frédéric AU - Guilbaud, Nicolas AU - Hoffmann, Jean-Sébastien AU - Larsson, Ola AU - Bousquet, Corinne AU - Pyronnet, Stéphane AU - Martineau, Yvan T1 - eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer PY - 2019/11/01/ AB - Pancreatic ductal adenocarcinoma (PDAC) relies on hyperactivated protein synthesis. Consistently, human and mouse PDAC lose expression of the translational repressor and mTOR target 4E-BP1. Using genome-wide polysome profiling, we here explore mRNAs whose translational efficiencies depend on the mTOR/4E-BP1 axis in pancreatic cancer cells. We identified a functional enrichment for mRNAs encoding DNA replication and repair proteins, including RRM2 and CDC6. Consequently, 4E-BP1 depletion favors DNA repair and renders DNA replication insensitive to mTOR inhibitors, in correlation with a sustained protein expression of CDC6 and RRM2, which is inversely correlated with 4E-BP1 expression in PDAC patient samples. DNA damage and pancreatic lesions induced by an experimental pancreatitis model uncover that 4E-BP1/2–deleted mice display an increased acinar cell proliferation and a better recovery than WT animals. Targeting translation, independently of 4E-BP1 status, using eIF4A RNA helicase inhibitors (silvestrol derivatives) selectively modulates translation and limits CDC6 expression and DNA replication, leading to reduced PDAC tumor growth. In summary, 4E-BP1 expression loss during PDAC development induces selective changes in translation of mRNA encoding DNA replication and repair protein. Importantly, targeting protein synthesis by eIF4A inhibitors circumvents PDAC resistance to mTOR inhibition. JF - JCI Insight JA - JCI Insight SN - 2379-3708 DO - 10.1172/jci.insight.121951 VL - 4 IS - 21 UR - https://doi.org/10.1172/jci.insight.121951 PB - The American Society for Clinical Investigation ER -